Professor Dr. Cheong Sok Ching is the Chief Scientific Officer of Cancer Research Malaysia, where she leads research aimed at improving cancer prevention, diagnosis, and treatment for Asian populations.
A cell and molecular biologist with more than two decades of experience, she has built a body of work that links scientific discovery to real benefits for patients and communities. Her team uses genome-wide CRISPR/Cas9 screening to uncover weak points in cancer cells and identify possible new treatment strategies, particularly for head and neck cancers, which disproportionately affect Asian populations.
She has also led the development of Malaysian therapeutic cancer vaccines, moving promising candidates from laboratory research toward early-phase clinical evaluation. Her work includes investigator-initiated clinical trials of immunotherapy, focused on generating evidence relevant to Asian patients and to healthcare systems with limited resources.
Knowing that innovation also has to reach people who face barriers to care, Professor Cheong developed MeMoSA® (Mobile Mouth Screening Anywhere). The digital health platform lets frontline healthcare workers capture oral images for remote assessment by clinicians, bringing early detection closer to underserved communities. MeMoSA has reached more than 1,800 people across 12 remote villages, and current regional research is evaluating AI-based image analysis to support clinical triage and wider implementation across Southeast Asia.
Professor Cheong is an Adjunct Professor at the Faculty of Dentistry, Universiti Malaya, and the fourth holder of the Dr. Siti Hasmah Mohd Ali Professorial Chair. She is a Fellow of the Academy of Sciences Malaysia and The World Academy of Sciences, and a recipient of the ASEAN-US Science Prize for Women.
Across all her work, she keeps her eyes on one outcome: making sure advances in cancer research lead to earlier diagnosis, more effective treatment, and better outcomes for people across Asia.



























